|

KTX-2001 + Darolutamide (NUBEQA®) Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • K36 Therapeutics, Inc.1

Indications

  • mCRPC1
  • Metastatic Castration-resistant Prostate Cancer, mCRPC1
  • Metastatic Castration-Resistant Prostate Cancer Patients1
  • mCRPC (Metastatic Castration-resistant Prostate Cancer)1
  • Metastatic Castration-resistant Prostate Cancer1

San Francisco, California1 trial

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

University of California San Francisco

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.